TASE Ends Sunday Mixed, Though Telco Shares Plunge

EU approval of drug for treating chemotherapy side-effects lifts Teva by just under 3%

Shelly Appelberg
Send in e-mailSend in e-mail
Shelly Appelberg

Comments